Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AV 101

Drug Profile

AV 101

Alternative Names: 4-Chlorokynurenine - VistaGen; 4-CL-KYN; 7-CL-KYNA; AV101; L-4-chlorokynurenine; L-4-CL-KYN

Latest Information Update: 22 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Artemis Neuroscience
  • Developer Baylor College of Medicine; National Institute of Mental Health; VistaGen Therapeutics
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Phase I Neuropathic pain; Suicidal ideation
  • Preclinical Psychiatric disorders
  • No development reported Epilepsy; Huntington's disease; Parkinson's disease

Most Recent Events

  • 19 Feb 2019 VistaGen Therapeutics has patent protection for AV 101 for treatment of Depression and Hyperalgesia in Japan
  • 19 Feb 2019 Phase-I clinical trials in Suicidal ideation (In volunteers) in USA (PO) before February 2019
  • 14 Feb 2019 9260346: relevant info already covered
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top